The Ortho Evra patch lawsuit settlement represents one of the more significant pharmaceutical liability resolutions of the 2000s. Johnson & Johnson’s subsidiary Ortho-McNeil paid more than $68.7 million to settle hundreds of lawsuits over the birth control patch by October 2008, with additional confidential settlements following in subsequent years. In total, roughly 4,000 lawsuits were filed in U.S.
state and federal courts, with plaintiffs alleging that the patch exposed women to dangerous levels of estrogen without adequate warning. At least 20 of those settled cases involved wrongful death claims. This article covers the health risks at the center of the litigation, how the settlement process unfolded, what women who were harmed actually received, and what the current legal landscape looks like for anyone still researching this issue. If you used the Ortho Evra patch and suffered a serious health event, understanding the history of this litigation matters — even if the window for filing new claims has largely closed.
Table of Contents
- What Were the Ortho Evra Lawsuits About, and Who Filed Them?
- How Did the Ortho Evra Settlement Process Unfold?
- The Health Risks That Drove the Litigation
- Canadian Litigation and the International Scope of the Claims
- What Is the Current Status of Ortho Evra Claims?
- How Ortho Evra Compares to Other Pharmaceutical Mass Torts
- What This Case Means for Pharmaceutical Accountability
- Conclusion
- Frequently Asked Questions
What Were the Ortho Evra Lawsuits About, and Who Filed Them?
The Ortho Evra patch was approved by the FDA in 2001 and marketed as a convenient alternative to daily birth control pills. Women applied a small adhesive patch to their skin once a week for three consecutive weeks, then went patch-free for one week. The problem, according to thousands of plaintiffs, was that the patch delivered approximately 60% more estrogen than a standard oral contraceptive. That elevated hormonal exposure significantly increased the risk of serious cardiovascular events. More than 2,400 women reported injuries connected to the patch, ranging from deep vein thrombosis and pulmonary embolism to strokes and heart attacks.
Some cases were fatal. The lawsuits alleged that Ortho-McNeil knew — or should have known — about these elevated risks and failed to adequately warn patients and prescribing physicians. One illustrative pattern in the litigation involved young, otherwise healthy women suffering strokes or blood clots with no prior cardiovascular history, events their treating physicians later linked to the heightened estrogen load from the patch. The cases were filed in both federal and state courts, and a significant number were consolidated into multidistrict litigation proceedings to streamline discovery and pretrial motions. This consolidation is standard practice in pharmaceutical mass tort cases and allowed plaintiffs’ attorneys to share evidence and resources while pursuing individual claims.
How Did the Ortho Evra Settlement Process Unfold?
Unlike a traditional class action settlement with a defined claims fund and a public submission process, the Ortho Evra litigation resolved primarily through individual settlements negotiated case by case. By October 2008, J&J had paid out more than $68.7 million across hundreds of resolved claims. That figure represented a rolling total, not a single lump-sum fund distributed to all plaintiffs equally. This distinction matters. In a class action, a court certifies a class of plaintiffs, approves a global settlement, and creates a formal process for members to submit claims and receive payment.
The Ortho Evra litigation did not follow that model in the United States. Instead, most cases settled privately, with amounts varying based on the severity of the injury, the strength of the evidence linking the patch to the plaintiff’s condition, and the terms negotiated by each plaintiff’s attorney. Many settlements included confidentiality agreements, which is why exact individual payouts are not publicly known. However, if a plaintiff’s case was weak on causation — meaning it was difficult to establish that the patch, rather than an underlying health condition, caused the injury — the settlement offer was likely lower or the case was more susceptible to dismissal. This is a meaningful limitation for anyone researching this litigation: the $68.7 million figure tells you the aggregate outcome, not what any individual plaintiff received.
The Health Risks That Drove the Litigation
The core medical allegation in the Ortho Evra lawsuits was straightforward: the patch delivered more estrogen than the product label initially disclosed, and that excess estrogen caused life-threatening cardiovascular events in otherwise healthy women. Estrogen at elevated doses increases the blood’s tendency to clot, which is the mechanism underlying deep vein thrombosis, pulmonary embolism, stroke, and heart attack. Pulmonary embolism — a blood clot that travels to the lungs — was among the most serious injuries alleged. It can be rapidly fatal, which explains why at least 20 wrongful death claims were part of the settled cases.
For comparison, the risk of blood clots from oral contraceptives was already a known and labeled risk, but plaintiffs argued the Ortho Evra patch presented a materially higher risk that was not communicated at the time many women began using it. The FDA did eventually require updated label warnings for the patch. In 2008, labeling changes more prominently disclosed the higher estrogen exposure associated with the patch compared to oral contraceptives. For many plaintiffs, that regulatory action came too late — they had already suffered injuries, sometimes irreversible ones, during years when the risk was downplayed or not clearly communicated in prescribing literature.
Canadian Litigation and the International Scope of the Claims
The Ortho Evra patch was marketed in Canada under the brand name Evra, and the health concerns crossed the border along with the product. A separate class action was filed in Canada against the manufacturer, and a confidential settlement was eventually reached covering at least 22 individual Canadian claims. The Canadian litigation illustrates how pharmaceutical mass torts sometimes develop in parallel across jurisdictions with different legal systems. Canadian class action procedures differ from U.S. practice, and the smaller number of settled claims reflects both the smaller patient population and the different legal pathways available to Canadian plaintiffs.
The confidential nature of that settlement means that the total value paid to Canadian claimants is not publicly known. For plaintiffs in other countries where the patch was sold, the international precedent set by both the U.S. and Canadian litigation was relevant context, even if direct claims in other jurisdictions faced different procedural hurdles. Pharmaceutical companies generally monitor mass tort outcomes closely across borders, and the scale of the U.S. litigation almost certainly influenced how J&J approached risk management for this product globally.
What Is the Current Status of Ortho Evra Claims?
As of early 2026, there is no active open class action settlement with a public claims submission process for Ortho Evra injuries. The litigation peaked between approximately 2007 and 2010, and the bulk of the cases were resolved either through the settlements that contributed to the $68.7 million total or through subsequent confidential agreements. The multidistrict litigation proceedings have concluded. Some law firms still list Ortho Evra as a practice area on their websites, but the current approach is case-by-case evaluation rather than participation in any active global settlement.
This means that any woman who believes she has an unresolved claim would need to consult with a personal injury or pharmaceutical liability attorney who can assess the specific facts, the applicable statute of limitations in her state, and whether any viable legal avenue remains open. The statute of limitations is the critical warning here. Most states impose a two-to-three year window from the date of injury or the date the plaintiff discovered (or should have discovered) the connection between the patch and her injury. Given that the majority of injuries occurred before 2010, the statute of limitations will have expired for most potential claims. An attorney can evaluate whether any exceptions — such as delayed discovery — might apply in a specific situation, but anyone expecting to file a new claim should approach this with realistic expectations.
How Ortho Evra Compares to Other Pharmaceutical Mass Torts
The Ortho Evra litigation followed a familiar trajectory in pharmaceutical mass tort law: initial product approval, post-market injury reports, regulatory action, label changes, and eventual litigation resolution. It is instructive to compare it to cases like the Yaz and Yasmin birth control litigation, which also centered on blood clot risks from hormonal contraceptives and similarly resulted in large aggregate settlements — Bayer paid over $2 billion to resolve Yaz-related claims.
The Ortho Evra settlement total, by comparison, was substantially smaller, reflecting both the number of plaintiffs and the litigation strategy employed. What distinguished Ortho Evra was the delivery mechanism: the patch format meant that, unlike a pill, patients couldn’t easily vary their dose or stop taking it mid-cycle without the equivalent of removing a medical device. That aspect of the product design became part of the plaintiffs’ argument that the hormonal exposure was harder for women to control than with oral contraceptives, adding a layer to the failure-to-warn theory.
What This Case Means for Pharmaceutical Accountability
The Ortho Evra litigation contributed to a broader shift in how regulators and courts evaluate hormonal contraceptive risks. The pressure from thousands of lawsuits — and the eventual $68.7 million in settlements — created financial and reputational consequences for J&J that informed how pharmaceutical companies disclose comparative risk data for similar products going forward.
It demonstrated that post-market surveillance failures carry real liability, even for products that were appropriately approved at launch. For women who used the Ortho Evra patch and suffered serious health consequences, the settlement history represents a partial accountability measure, though it came too late for those who died or suffered permanent disability. The litigation’s resolution does not mean the product was vindicated — it means the parties reached financial agreements that avoided further trial risk on both sides.
Conclusion
The Ortho Evra patch lawsuits resulted in more than $68.7 million paid by Johnson & Johnson to settle hundreds of claims, with the litigation peaking between 2007 and 2010. The cases centered on the patch’s elevated estrogen delivery — roughly 60% higher than oral contraceptives — and its association with blood clots, strokes, heart attacks, and pulmonary embolism. At least 20 wrongful death claims were among those settled, and a separate confidential settlement resolved at least 22 Canadian claims.
If you are researching this topic because you or someone you know was harmed by the Ortho Evra patch, consult a pharmaceutical liability attorney promptly to evaluate whether any legal avenue remains available given applicable statutes of limitations. There is no active open claims process as of early 2026. For anyone seeking general information about this litigation’s outcome, the record shows a case that resulted in meaningful corporate accountability through the courts, even as the bulk of individual settlement terms remain confidential.
Frequently Asked Questions
Was there a class action settlement fund for Ortho Evra that I can still submit a claim to?
No. As of early 2026, there is no active class action settlement with a public claims process for Ortho Evra injuries. The litigation was resolved primarily through individual and confidential settlements rather than a global class action fund.
How much did Johnson & Johnson pay to settle Ortho Evra lawsuits?
By October 2008, J&J had paid more than $68.7 million to settle hundreds of lawsuits. Additional confidential settlements were reached after that date, so the total amount paid is likely higher, though the full figure has never been publicly disclosed.
What injuries were linked to the Ortho Evra patch in these lawsuits?
Plaintiffs reported deep vein thrombosis, pulmonary embolism, stroke, and heart attack. At least 20 cases involved wrongful deaths. The elevated risk was attributed to the patch delivering approximately 60% more estrogen than a typical birth control pill.
Can I still file a lawsuit over the Ortho Evra patch?
Possibly, depending on when your injury occurred and the statute of limitations in your state. Most states have a two-to-three year window from the date of injury or discovery of the connection. Given that the bulk of injuries occurred before 2010, most potential claims may be time-barred. An attorney can assess your specific situation.
Was there a separate settlement in Canada?
Yes. A class action was filed in Canada over the Evra patch (the Canadian brand name), and a confidential settlement was reached covering at least 22 individual Canadian claims. The total value of the Canadian settlement has not been publicly disclosed.
Did the FDA take any action in response to the Ortho Evra health concerns?
Yes. The FDA required updated labeling for the Ortho Evra patch, with more prominent disclosure of the elevated estrogen exposure compared to oral contraceptives. These label changes were implemented in 2008, several years after the product launched and after many of the injuries at issue in the litigation had already occurred.